Atavistik Bio logo

Atavistik Bio

Precision allosteric therapeutics inspired by the body’s natural regulators

42 employees · est. 2021 · Cambridge, United States

VS
Incyclix Bio logo

Incyclix Bio

Regaining Cell Cycle Control

13 employees · est. 2020 · Durham, United States

Incyclix Bio is the older company (2021 vs 2020).

Side-by-Side Comparison

Atavistik Bio Incyclix Bio
Founded
2021 2020 older
Headquarters
Cambridge, United States Durham, United States
Employees
42 13
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care, Health and Wellness
Funding Stage
Series B Series B
Total Funding
$260.00M $64.00M
Funding Rounds
5 5
Services
Not tracked yet Development of selective CDK inhibitors, Clinical development of INX-315, Research and discovery in oncology
Target Customers
Not tracked yet Cancer patients, Healthcare professionals, Oncologists, Biotech investors, Pharmaceutical researchers
Taxonomy
Drug Discovery, Metabolism, Allosteric Precision Therapeutics, Biological Regulators, Proprietary Screening Technology, AI-enabled Drug Discovery Platform, Novel Allosteric Sites, Protein Targets, RNA Targets, Structural Insights, Small Molecule Therapeutics Design Cell Cycle Control, Precision Treatments, CDK2 Inhibitor, Cancer Therapeutics, Small Molecule Inhibitors, Oncology Drug Development, Cyclin-Dependent Kinases, Tumor Types, Ovarian Cancer, Breast Cancer, Lung Cancer, Clinical Stage Biotechnology, Aberrant Proliferation, Drug Discovery, Research Triangle Park
Website
atavistikbio.com incyclixbio.com
Atavistik Bio logo

About Atavistik Bio

Atavistik Bio is a biotechnology startup that focuses on drug discovery inspired by metabolism. The company's proprietary screening technology, which utilizes the body's natural regulators, combined with an AI-enabled drug discovery platform, enables the identification of novel allosteric sites for...

Incyclix Bio logo

About Incyclix Bio

Incyclix Bio, a pioneer founded in 2020, is at the forefront of biotechnology innovation with its next-generation approach in cell cycle control. Under the slogan "Regaining Cell Cycle Control", the company is committed to developing precision treatments targeting the aberrant proliferation that is...

We will tell you when either one moves

BounceWatch watches Atavistik Bio and Incyclix Bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Atavistik Bio and Incyclix Bio — by email.

Frequently Asked Questions

Atavistik Bio — Precision allosteric therapeutics inspired by the body’s natural regulators. Incyclix Bio — Regaining Cell Cycle Control. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Atavistik Bio has raised $260.00M while Incyclix Bio has raised $64.00M.
Atavistik Bio and Incyclix Bio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Atavistik Bio with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Atavistik Bio on 9 Jun 2026, and Incyclix Bio on 4 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy